• / Free eNewsletters & Magazine
  • / My Account
Home>Finance>Food>Food And Drug Administration

Food And Drug Administration

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Atrantil Expands Retail Presence to Another Major Regional Retailer

    Atrantil Expands Retail Presence to Another Major Regional Retailer

  2. FDA Approves New Drug Application for RAYALDEE® to Treat Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Stage 3-4 Chronic Kidney Disease

    FDA Approves New Drug Application for RAYALDEE® to Treat Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Stage 3-4 Chronic Kidney Disease

  3. Cerus Announces Agreement with BARDA for Potential Funding of up to Approximately $180 Million to Advance Its INTERCEPT Red Blood Cell Program

    Cerus Announces Agreement with BARDA for Potential Funding of up to Approximately $180 Million to Advance Its INTERCEPT Red Blood Cell Program

  4. CHIASMA, INC. INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

    CHIASMA, INC. INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

  5. Could this tiny new implant be the best treatment option for opioid addicts?

    Could this tiny new implant be the best treatment option for opioid addicts?

  6. Results of Phase 2 Study of Merck’s Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cilastatin Presented at ASM Microbe

    Results of Phase 2 Study of Merck’s Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cilastatin Presented at ASM Microbe

  7. GlaxoSmithKline COPD Triple Combination Study Shows Improved Lung Function Vs Rival

    GlaxoSmithKline COPD Triple Combination Study Shows Improved Lung Function Vs Rival

  8. Analytical Method Validation Under Good Laboratory Practices (GLPs) Webinar - Research and Markets

    Analytical Method Validation Under Good Laboratory Practices (GLPs) Webinar - Research and Markets

  9. Pfizer Announces FDA Advisory Committees’ Recommend ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride) Extended-Release Capsules for Approval

    Pfizer Announces FDA Advisory Committees’ Recommend ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride) Extended-Release Capsules for Approval

  10. Adamis's stock plunges after FDA requires more tests for NDA product

    Adamis's stock plunges after FDA requires more tests for NDA product

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.